2Mandema JW, Kaiko RF, Oshlack B, et al. Characterization and validation of a pharmacokinetic model for controlled release oxycodone [ J ]. Br J Clin Pharmacol, 1996,42 (6) : 747-756.
3[1]Lin CC, Ward SE. Patient-related barriers to cancer pain management in Taiwan, Cancer Nursing,1995, 18: 16～22.
4[3]Bonica JJ. Management of Cancer Pain. Recent Results of Cancer Research, 1984, 89:13～27.
5[4]Cleeland CS, Gonin R, Hatfield AK, et al: Pain and Its Treatment in Outpatients with Metastatic Cancer. N Engl J Med, 1994, 330 ～592.
6[5]Ward SE, Hernandez L. Patient-related barriers to management of cancer pain in Puerto Rico. Pain,1994, 58: 233 ～238.
7[6]Chung TK, French P, Chan S. Patients- related barriers to cancer pain management in a palliative care setting in Hong Kong. Cancer Nursing, 1999,June, 22: 196～ 203.
8Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be r-oploid receptor mediated [J]. Pain ,1997,73 : 151-157.
9Nielsen CK, Boss FB, Shahrdad L, el al. Oxycodone and moTphine have dis- tinctly different pbarmacologlcal profiles: Radioligand blinding and behavioural studies in two rat models d neuropathic pain [ J ]. Pain,2007,132 : 289-300.
10Gaveriaux-Ruff C, Kim'fer BL. Opioid receptor genes inactivated in mice : the highlights [J]. Neuropeptdes,2002,36(2-3) : 62-71.
